News
October 30, 2025
Other news to note for Oct. 29, 2025
Biopharma happenings, including deals and partnerships, and other news in brief: Empirico, GSK, Locus, Milliporesigma, Novartis, Pacira, Promega, Qilu, Tourmaline, Viatris.
**A Roundup of Biopharma Activity: Deals, Partnerships, and More**
October 29, 2025, saw a flurry of activity in the biopharmaceutical sector, with several companies announcing deals, partnerships, and other significant developments. Here's a quick look at some of the noteworthy news:
Empirico announced a new research collaboration with GSK, GlaxoSmithKline, focused on identifying novel drug targets for a specific disease area. While the exact terms of the deal weren't disclosed, it's understood that the collaboration will leverage Empirico's data-driven drug discovery platform and GSK's extensive research and development capabilities. This partnership aims to accelerate the development of new therapies by identifying promising targets more efficiently.
Locus Biosciences revealed a strategic partnership with Qilu Pharmaceutical, a major player in the Asian market. The collaboration centers around the development and commercialization of Locus's CRISPR-enhanced phage therapies targeting bacterial infections. This move allows Locus to expand its global reach and tap into Qilu's manufacturing and distribution network, potentially bringing innovative antibacterial treatments to a wider patient population.
Milliporesigma, a leading life science company, unveiled a new initiative to support biomanufacturing innovation. The company plans to invest in infrastructure and training programs to help biopharmaceutical companies optimize their manufacturing processes and reduce costs. This initiative addresses the growing demand for efficient and scalable biomanufacturing solutions.
Novartis announced positive preliminary results from a clinical trial evaluating a novel therapy for a rare genetic disorder. The data suggests that the therapy could significantly improve the quality of life for patients affected by the condition. Further details are expected to be presented at an upcoming medical conference.
Pacira BioSciences reported strong sales growth for its non-opioid pain management product. The company continues to focus on expanding access to non-opioid alternatives for post-surgical pain relief, addressing the ongoing opioid crisis.
Promega Corporation announced the launch of a new suite of tools for cell and gene therapy research. These tools are designed to streamline the development and manufacturing of cell and gene therapies, helping to accelerate the delivery of these potentially life-changing treatments to patients.
Tourmaline Bio, a company focused on developing therapies for endocrine diseases, secured a new round of funding to support its clinical development programs. The funding will enable the company to advance its pipeline of novel therapies for patients with unmet medical needs.
Finally, Viatris announced the
October 29, 2025, saw a flurry of activity in the biopharmaceutical sector, with several companies announcing deals, partnerships, and other significant developments. Here's a quick look at some of the noteworthy news:
Empirico announced a new research collaboration with GSK, GlaxoSmithKline, focused on identifying novel drug targets for a specific disease area. While the exact terms of the deal weren't disclosed, it's understood that the collaboration will leverage Empirico's data-driven drug discovery platform and GSK's extensive research and development capabilities. This partnership aims to accelerate the development of new therapies by identifying promising targets more efficiently.
Locus Biosciences revealed a strategic partnership with Qilu Pharmaceutical, a major player in the Asian market. The collaboration centers around the development and commercialization of Locus's CRISPR-enhanced phage therapies targeting bacterial infections. This move allows Locus to expand its global reach and tap into Qilu's manufacturing and distribution network, potentially bringing innovative antibacterial treatments to a wider patient population.
Milliporesigma, a leading life science company, unveiled a new initiative to support biomanufacturing innovation. The company plans to invest in infrastructure and training programs to help biopharmaceutical companies optimize their manufacturing processes and reduce costs. This initiative addresses the growing demand for efficient and scalable biomanufacturing solutions.
Novartis announced positive preliminary results from a clinical trial evaluating a novel therapy for a rare genetic disorder. The data suggests that the therapy could significantly improve the quality of life for patients affected by the condition. Further details are expected to be presented at an upcoming medical conference.
Pacira BioSciences reported strong sales growth for its non-opioid pain management product. The company continues to focus on expanding access to non-opioid alternatives for post-surgical pain relief, addressing the ongoing opioid crisis.
Promega Corporation announced the launch of a new suite of tools for cell and gene therapy research. These tools are designed to streamline the development and manufacturing of cell and gene therapies, helping to accelerate the delivery of these potentially life-changing treatments to patients.
Tourmaline Bio, a company focused on developing therapies for endocrine diseases, secured a new round of funding to support its clinical development programs. The funding will enable the company to advance its pipeline of novel therapies for patients with unmet medical needs.
Finally, Viatris announced the
Category:
Technology